NDOH
Org Charts & Departments
CUROSURF
UPDATED PI…
STRATEGY…
So…what else???
LISA
Practical : Global Best Practice
In Person Training
CME & Competitions
Boris Kramer
• Tridente & Regional Video / Lecture Sessions
• New PI, Detail Materials, Marketing Materials - LISA
Continue to Uplift & Train
Get onto the journey of Global Best Practice
CUROSURF - UPDATED PI…
AGENDA
 TRAINING :
- LISA Detail Aid
- OPTIMIST & Cochrane trial summaries – explanation & execution
- New PI & PIL
- New Packaging
 Latest Marketing Materials :
- Neonatal LISA competition
- Dosage magnets
- A6 Dosage
- Gently Dose it Stickers
- Curosurf and Cayona stickers
- Competition
PRIORITIES
USANA
PMG
NDOH - Executive Summary
• In Neonatology, the use of meta-analysis and systemic reviews is of particular importance due to the limited population size and
therefore the limited sample size of RCTs
• The latest Cochrane Review (Singh et al 2015 : Comparison of animal-derived surfactants …) found a significant increase in the risk of
mortality prior to discharge, death or oxygen requirement at 36 weeks’ postmenstrual age, in infants treated with modified bovine
minced lung surfactant extract (beractant or surfactant TA) compared with porcine minced lung surfactant extract (poractant alfa).3
• In Surfactant Replacement Therapy, the differences in administration technique and volume between Poractant Alfa and Beractant
means that Double Blind Trials are not possible.
• Poractant Alfa is licensed at a dose ranging from 100-200mg/kg and the majority of evidence is based on a 200mg/kg dose. As
Beractant is only licensed at a dose of 100mg/kg, Poractant Alfa and Beractant cannot be classed as Therapeutic Equivalents.
• European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome in Preterm Infants – 2013 Update
recommend that Poractant alfa in an initial dose of 200mg/kg is better than 100mg/kg of poractant alfa or beractant for treatment of
RDS (with GRADE A level of evidence). These Guidelines are endorsed by the European Association of Perinatal Medicine (EAPM).
• Poractant Alfa at a dose of 200mg/kg in addition to improving survival will:
• Reduce exposure to Mechanical Ventilation by Faster Weaning
• Reduce exposure to Mechanical Ventilation by Earlier Extubation
• Reduce the need for reintubation for redosing
• Irrespective of whether the improvement in outcomes is as a result of the biophysical properties of Poractant Alfa or the dose effect,
the evidence clearly demonstrates an improvement when using Poractant Alfa at a dose of 200mg/kg, which will ultimately benefit the
patient….Cochrane review 2015.
• As a result of the evidence and experience when using Poractant Alfa, globally it is the market leader with >73% Market Share in
both developed & developing nations alike.
STG Submission